ISDA

Entry Detail

PDB ID:

3L54

Keywords:

TRANSFERASE

Title:

Structure of Pi3K gamma with inhibitor

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

unidentified baculovirus

PDB Version:

Deposition Date:

2009-12-21

Release Date:

2010-06-30

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.30 Å

R-Value Free:

0.27

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Chain IDs:A
Chain Length:966
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P48736 Pfam ID:PF00794, PF00792, PF00613, PF00454 EC:2.7.1.137

Ligand Molecules

LXX

SO4

Primary Citation

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.

Knight, S.D, Adams, N.D, Burgess, J.L, Chaudhari, A.M, Darcy, M.G, Donatelli, C.A, Luengo, J.I, Newlander, K.A, Parrish, C.A, Ridgers, L.H, Sarpong, M.A, Schmidt, S.J, Van Aller, G.S, Carson, J.D, Diamond, M.A, Elkins, P.A, Gardiner, C.M, Garver, E, Gilbert, S.A, Gontarek, R.R, Jackson, J.R, Kershner, K.L, Luo, L, Raha, K, Sherk, C.S, Sung, C.M, Sutton, D, Tummino, P.J, Wegrzyn, R.J, Auger, K.R, Dhanak, D.Show

ACS Med Chem Lett 1 39 43 (2010)

PMID: 24900173 DOI: 10.1021/ml900028r

Abstact

Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

Legend

Protein

Chemical

Disease

Primary Citation of related structures